Literature DB >> 28774562

Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Yoichi Furuya1, Girish S Kirimanjeswara1, Sean Roberts1, Rachael Racine1, Jennifer Wilson-Welder1, Alan M Sanfilippo1, Sharon L Salmon1, Dennis W Metzger2.   

Abstract

We report that IgA-/- mice exhibit specific defects in IgG antibody responses to various polysaccharide vaccines (Francisella tularensis LPS and Pneumovax), but not protein vaccines such as Fluzone. This defect further included responses to polysaccharide-protein conjugate vaccines (Prevnar and Haemophilus influenzae type b-tetanus toxoid vaccine). In agreement with these findings, IgA-/- mice were protected from pathogen challenge with protein- but not polysaccharide-based vaccines. Interestingly, after immunization with live bacteria, IgA+/+ and IgA-/- mice were both resistant to lethal challenge and their IgG anti-polysaccharide antibody responses were comparable. Immunization with live bacteria, but not purified polysaccharide, induced production of serum B cell-activating factor (BAFF), a cytokine important for IgG class switching; supplementing IgA-/- cell cultures with BAFF enhanced in vitro polyclonal IgG production. Taken together, these findings show that IgA deficiency impairs IgG class switching following vaccination with polysaccharide antigens and that live bacterial immunization can overcome this defect. Since IgA deficient patients also often show defects in antibody responses following immunization with polysaccharide vaccines, our findings could have relevance to the clinical management of this population.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-polysaccharide IgG; Bacterial infections; IgA; IgA immunodeficiency; Vaccines

Mesh:

Substances:

Year:  2017        PMID: 28774562      PMCID: PMC6314215          DOI: 10.1016/j.vaccine.2017.07.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

Review 1.  B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory".

Authors:  F Martin; J F Kearney
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

2.  Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens.

Authors:  F Martin; A M Oliver; J F Kearney
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

3.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

Review 4.  Physiology of IgA and IgA deficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

5.  Human IgA activates the complement system via the mannan-binding lectin pathway.

Authors:  A Roos; L H Bouwman; D J van Gijlswijk-Janssen; M C Faber-Krol; G L Stahl; M R Daha
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

6.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

7.  Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes.

Authors:  G R Harriman; M Bogue; P Rogers; M Finegold; S Pacheco; A Bradley; Y Zhang; I N Mbawuike
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

Review 8.  Humoral immunodeficiency in recurrent upper respiratory tract infections. Some basic, clinical and therapeutic features.

Authors:  J Daele; A F Zicot
Journal:  Acta Otorhinolaryngol Belg       Date:  2000

9.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

10.  Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS.

Authors:  G Sandström; A Sjöstedt; T Johansson; K Kuoppa; J C Williams
Journal:  FEMS Microbiol Immunol       Date:  1992-10
View more
  3 in total

1.  Specialization of mucosal immunoglobulins in pathogen control and microbiota homeostasis occurred early in vertebrate evolution.

Authors:  Zhen Xu; Fumio Takizawa; Elisa Casadei; Yasuhiro Shibasaki; Yang Ding; Thomas J C Sauters; Yongyao Yu; Irene Salinas; J Oriol Sunyer
Journal:  Sci Immunol       Date:  2020-02-07

2.  The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.

Authors:  Clare M Williams; Sreeja Roy; Danielle Califano; Andrew N J McKenzie; Dennis W Metzger; Yoichi Furuya
Journal:  J Virol       Date:  2021-09-01       Impact factor: 5.103

3.  Effectiveness of Haemophilus influenzae type b vaccination after splenectomy - impact on selected immunological parameters.

Authors:  Ewelina Grywalska; Dorota Siwicka-Gieroba; Michał Mielnik; Martyna Podgajna; Krzysztof Gosik; Wojciech Dąbrowski; Jacek Roliński
Journal:  Hum Vaccin Immunother       Date:  2018-11-05       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.